Story perspectives

Gilead Acquires Tubulis for $5 Billion to Boost ADC Research

4/7/2026

Summary

Story summary

Gilead Sciences finalized the Tubulis GmbH acquisition for up to $5 billion, including $3.15 billion upfront and up to $1.85 billion in milestones.
Tubulis specializes in antibody-drug conjugates, with lead candidate TUB-040 in Phase 1b/2 trials for platinum-resistant ovarian cancer and NSCLC.
Gilead will integrate Tubulis as a dedicated ADC research organization, following its recent purchases of Arcellx and Ouro Medicines.

History

Historical Context

Gilead Sciences, founded in 1987, has strategically expanded its oncology portfolio through significant acquisitions, including Kite Pharma in 2017 for $11.9 billion, which introduced CAR T-cell therapies like Yescarta. In 2023, Gilead acquired Tubulis GmbH for $5 billion, further enhancing its focus on innovative cancer treatments, particularly for challenging conditions like platinum-resistant ovarian cancer, potentially transforming patient care in oncology.

1 of 2

Story summary

Gilead Sciences finalized the Tubulis GmbH acquisition for up to $5 billion, including $3.15 billion upfront and up to $1.85 billion in milestones.
Tubulis specializes in antibody-drug conjugates, with lead candidate TUB-040 in Phase 1b/2 trials for platinum-resistant ovarian cancer and NSCLC.
Gilead will integrate Tubulis as a dedicated ADC research organization, following its recent purchases of Arcellx and Ouro Medicines.

1 / 2